Literature DB >> 27491554

The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1/3.

Alberto Righi1, Marco Faustini-Fustini2, Luca Morandi3, Valentina Monti3, Sofia Asioli3, Diego Mazzatenta4, Antonella Bacci5, Maria Pia Foschini3.   

Abstract

The spectrum of corticotroph cell adenomas is very wide. Though rarely, silent corticotroph cell adenomas (SCA) may transform into corticotroph cell adenomas associated with Cushing's disease (CD). The aim of the study was to investigate the role of prohormone convertase 1/3 (PC1/3) in the transformation of SCA into CD. We reviewed the records of 1259 consecutive endoscopic endonasal procedures for pituitary adenomas from 1998 to 2013. Of these, 132 were CD and 44 were SCA. During the follow-up, three patients with SCA showed a clear transformation from SCA into CD and underwent surgery once again to remove the recurrent tumour. The PC1/3 expression was analysed by both immunohistochemistry and quantitative real time-polymerase chain reaction (qRT-PCR) in primary and recurrent tumours. The immunohistochemical PC1/3 expression was negative or weak in the three patients in the initial phase of SCA, while a strong expression was observed in the majority of neoplastic cells in tissue specimens obtained from the same three patients at the time of recurrence as CD. The immunohistochemical PC1/3 expression showed a strict correlation with the PC1/3 levels obtained by qRT-PCR. In 14 cases of SCA with no change of phenotype during the follow-up, the immunohistochemical PC1/3 expression was low and strictly associated with the level of PC1/3 obtained by qRT-PCR both in primary (14/14 cases) and in recurrent tumours (4/4 cases). Our study provides insight into the crucial role of the PC1/3 protein in the transformation of phenotype from SCA to CD.

Entities:  

Keywords:  Cushing’s disease; Metamorphosis; Pituitary adenoma; Prohormone convertase

Mesh:

Substances:

Year:  2016        PMID: 27491554     DOI: 10.1007/s12020-016-1028-0

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  44 in total

1.  The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas.

Authors:  Hiroshi Nishioka; Naoko Inoshita; Ozgur Mete; Sylvia L Asa; Kyohei Hayashi; Akira Takeshita; Noriaki Fukuhara; Mitsuo Yamaguchi-Okada; Yasuhiro Takeuchi; Shozo Yamada
Journal:  Endocr Pathol       Date:  2015-12       Impact factor: 3.943

2.  Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease.

Authors:  Gérald Raverot; Anne Wierinckx; Emmanuel Jouanneau; Carole Auger; Françoise Borson-Chazot; Joël Lachuer; Michel Pugeat; Jacqueline Trouillas
Journal:  Eur J Endocrinol       Date:  2010-04-12       Impact factor: 6.664

3.  Cushing's disease with periodic hormonogenesis: one explanation for paradoxical response to dexamethasone.

Authors:  R D Brown; G R Van Loon; D N Orth; G W Liddle
Journal:  J Clin Endocrinol Metab       Date:  1973-03       Impact factor: 5.958

4.  A decade of pituitary microsurgery. The Herbert Olivecrona lecture.

Authors:  C B Wilson
Journal:  J Neurosurg       Date:  1984-11       Impact factor: 5.115

5.  Clinically silent corticotroph tumors of the pituitary gland.

Authors:  B W Scheithauer; A J Jaap; E Horvath; K Kovacs; R V Lloyd; F B Meyer; E R Laws; W F Young
Journal:  Neurosurgery       Date:  2000-09       Impact factor: 4.654

6.  Localization of prohormone convertases 1/3 and 2 in the human pituitary gland and pituitary adenomas: analysis by immunohistochemistry, immunoelectron microscopy, and laser scanning microscopy.

Authors:  I Takumi; D F Steiner; N Sanno; A Teramoto; R Y Osamura
Journal:  Mod Pathol       Date:  1998-03       Impact factor: 7.842

7.  The prevalence and characteristic features of cyclicity and variability in Cushing's disease.

Authors:  Krystallenia I Alexandraki; Gregory A Kaltsas; Andrea M Isidori; Scott A Akker; William M Drake; Shern L Chew; John P Monson; G Michael Besser; Ashley B Grossman
Journal:  Eur J Endocrinol       Date:  2009-03-16       Impact factor: 6.664

8.  Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation.

Authors:  Andrea G Lania; Stefano Ferrero; Rosario Pivonello; Giovanna Mantovani; Erika Peverelli; Antonella Di Sarno; Paolo Beck-Peccoz; Anna Spada; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2009-11-04       Impact factor: 5.958

9.  Differential gene expression in ACTH -secreting and non-functioning pituitary tumors.

Authors:  Toru Tateno; Hajime Izumiyama; Masaru Doi; Takanobu Yoshimoto; Masayoshi Shichiri; Naoko Inoshita; Kenichi Oyama; Shozo Yamada; Yukio Hirata
Journal:  Eur J Endocrinol       Date:  2007-12       Impact factor: 6.664

10.  Cushing's disease cycling over ten years.

Authors:  V Popovic; D Micic; M Nesovic; T Howlett; I Doniach; A Kendereski; P Djordjevic; D Manojlovic; J Micic; M Besser
Journal:  Exp Clin Endocrinol       Date:  1990-11
View more
  16 in total

Review 1.  Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.

Authors:  Fabienne Langlois; Dawn Shao Ting Lim; Chris G Yedinak; Isabelle Cetas; Shirley McCartney; Justin Cetas; Aclan Dogan; Maria Fleseriu
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

Review 2.  Aggressive nonfunctioning pituitary neuroendocrine tumors.

Authors:  Sérgio Portovedo; Leonardo Vieira Neto; Christina Maeda Takiya; Leandro Miranda-Alves; Paula Soares; Denise Pires de Carvalho
Journal:  Brain Tumor Pathol       Date:  2022-06-20       Impact factor: 3.154

Review 3.  Recent Understanding and Future Directions of Recurrent Corticotroph Tumors.

Authors:  José Miguel Hinojosa-Amaya; César Ernesto Lam-Chung; Daniel Cuevas-Ramos
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-26       Impact factor: 5.555

4.  Long-Term Use of Temozolomide as Safe and Effective Therapy for an Aggressive Corticotroph Adenoma in a Very Old Patient.

Authors:  Maria Chiara Decaroli; Anna Ansaloni; Maria Laura Monzani; Marco Losa; Elena Zunarelli; Vincenzo Rochira; Bruno Madeo
Journal:  J Endocr Soc       Date:  2021-04-10

Review 5.  Histopathological classification of non-functioning pituitary neuroendocrine tumors.

Authors:  Emilija Manojlovic-Gacic; Britt Edén Engström; Olivera Casar-Borota
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 6.  Clinical and Pathological Aspects of Silent Pituitary Adenomas.

Authors:  Juliana Drummond; Federico Roncaroli; Ashley B Grossman; Márta Korbonits
Journal:  J Clin Endocrinol Metab       Date:  2019-07-01       Impact factor: 5.958

7.  A clinicoradiological analysis of silent corticotroph adenomas after the introduction of pituitary-specific transcription factors.

Authors:  Abhijit Goyal-Honavar; Sauradeep Sarkar; H S Asha; Nitin Kapoor; Rajesh Balakrishnan; Harshad Vanjare; Geeta Chacko; Ari G Chacko
Journal:  Acta Neurochir (Wien)       Date:  2021-06-28       Impact factor: 2.216

Review 8.  Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.

Authors:  Masaaki Yamamoto; Takahiro Nakao; Wataru Ogawa; Hidenori Fukuoka
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-16       Impact factor: 5.555

9.  Differential Expression of MicroRNAs in Silent and Functioning Corticotroph Tumors.

Authors:  Araceli García-Martínez; Antonio C Fuentes-Fayos; Carmen Fajardo; Cristina Lamas; Rosa Cámara; Beatriz López-Muñoz; Ignacio Aranda; Raúl M Luque; Antonio Picó
Journal:  J Clin Med       Date:  2020-06-12       Impact factor: 4.241

Review 10.  Recent advances in understanding corticotroph pituitary tumor initiation and progression.

Authors:  Ulrich Renner; Denis Ciato; Günter K Stalla
Journal:  F1000Res       Date:  2018-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.